Purpose
We compared the local control rate and toxicity of stereotactic ablative radiotherapy (SABR) versus wedge resection for colorectal pulmonary metastases.
Materials and Methods
We retrospectively reviewed medical charts and imaging of patients treated with SABR or wedge resection between 2010 and 2017 at a single institution.
Results
A total of 404 patients were treated with local therapy for 528 pulmonary metastatic lesions. While surgery was frequently used upfront for smaller, solitary metastases without other site involvement, SABR was often used for larger, multiple lesions and disease burdens beyond the lungs. The 3-year local control rate was 88.6% following surgery, which was not significantly different from that with SABR at 86.7% (p=0.174). No major postoperative complications or mortality were observed in the surgery group, and 2.8% of patients in the SABR group experienced grade 3-4 radiation pneumonitis.
Conclusion
SABR was used in patients with a higher risk of progression compared to those undergoing surgery, yet it has similar local control rates to wedge resection.
Citations
Citations to this article as recorded by
Percutaneous Cryoablation Under Local Anesthesia for Pulmonary Metastases From Colorectal Cancer: Long‐Term Outcomes From a Single‐Institution Retrospective Cohort Shun Yorimori, Kaoru Kaseda, Yusuke Aoki, Kosuke Sugino, Takahiro Suzuki, Yu Okubo, Shigeki Suzuki, Kyohei Masai, Masashi Tamura, Masanori Inoue, Hideki Yashiro, Seishi Nakatsuka, Yoshikane Yamauchi, Yotaro Izumi, Masafumi Kawamura, Masahiro Jinzaki, Keis Cancer Reports.2026;[Epub] CrossRef
Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer Hasan Al-Sattar, Esele Okondo, Amir Mashia Jaafari, Inesh Sood, Jakob Hassan Dinif, Su Yin Lim, Charlotte Hafkamp, Irene Chong, Joao R. Galante, Sola Adeleke International Journal of Molecular Sciences.2025; 26(21): 10302. CrossRef
Particle therapy is a promising and evolving modality of radiotherapy that can be used to treat tumors that are radioresistant to conventional photon beam radiotherapy. It has unique biological and physical advantages compared with conventional radiotherapy. The characteristic feature of particle therapy is the “Bragg peak,” a steep and localized peak of dose, that enables precise delivery of the radiation dose to the tumor while effectively sparing normal organs. Especially, the charged particles (e.g., proton, helium, carbon) cause a high rate of energy loss along the track, thereby leading to high biological effectiveness, which makes particle therapy attractive. Using this property, the particle beam induces more severe DNA double-strand breaks than the photon beam, which is less influenced by the oxygen level. This review describes the general biological and physical aspects of particle therapy for oncologists, including non-radiation oncologists and beginners in the field.
Citations
Citations to this article as recorded by
The global landscape of particle beam radiotherapy trials over 15 years Wei Chen, Chenfei Wu, Mingying Xiao, Runzhe Chen, Lanlan Guo, Haoyue Hu, Xuan Li, Baiqiang Dong, Yuanyang Huang, Ming Chen Cancer Pathogenesis and Therapy.2026; 4(3): 219. CrossRef
Evaluation of the biological effectiveness of L-4-boronophenylalanine in glioblastomas Xiaohong Zhang, Jiaomei Bai, Diyun Shu, Changran Geng, Aoyun Guo, Li Li, Aleksandr Kichigin, Qichun Wei, Xiaobin Tang, Yuanhao Liu Applied Radiation and Isotopes.2026; 231: 112505. CrossRef
Robustness evaluation of carbon ion radiotherapy for ventricular tachycardia Yuya Miyasaka, Mayumi Ichikawa, Hikaru Souda, Yuki Tominaga, Yuhi Wakisaka, Hongbo Chai, Miyu Ishizawa, Masashi Koto, Takeo Iwai Physics and Imaging in Radiation Oncology.2026; 37: 100932. CrossRef
Multi-angle beam range measurement framework for carbon-ion radiotherapy using a commercial multi-layer ionization chamber Soorim Han, YongCheol Kwon, Taegeon Oh, Eunho Lee, Eun Kyu Kim, Tae Ho Kim, Dohyeon Yoo, Sangmin Lee, Changhwan Kim, Min Cheol Han, Chae-Seon Hong, Jin Sung Kim Zeitschrift für Medizinische Physik.2026;[Epub] CrossRef
Personalised Dosimetry in Nuclear Medicine: Bridging Physics, Biology and AI for Next Generation Radiopharmaceutical Therapy Joycie Shanmugiah, Jin Su Kim Nuclear Medicine and Molecular Imaging.2026; 60(3): 221. CrossRef
The Clinical Evidence and Applications of Particle Therapy Anika Patel, Kayeong Shin, Anna Lee The Cancer Journal.2026;[Epub] CrossRef
Evolution of Particle Radiotherapy: From Physical to Dual Targeting in Precision Medicine Heying Yao, Fan Zheng, Yan Zhong, Huanfeng Tian, Zhiyan Li, Hua Zhu, Zhi Yang, Hong Zhang, Mei Tian, Wenbin Zeng Molecular Pharmaceutics.2026; 23(5): 2829. CrossRef
Fundamental Physical Principles and Clinical Applications of Proton Therapy: A Comprehensive Review Crownbirth Ebipade Eki, Anita Franklin Akpolile, Godwin Kparobo Agbajor Nigerian Journal of Theoretical and Environmental Physics.2026; 4(1): 74. CrossRef
Development of a dual-energy CBCT calibration method for accurate electron density estimation in preclinical small-animal proton therapy dose planning I-Chun Cho, Tanaporn Buangklang, Chien-Hau Chu, Shen-Hao Lee, Chien-Yu Lin, Chun-Chieh Wang, Kang-Hsing Fan, Tsi-Chian Chao Applied Radiation and Isotopes.2026; 234: 112631. CrossRef
Cold-spot driven local failure after stereotactic body radiation therapy for colorectal liver metastases Hyunju Shin, Jeong Il Yu, Hee Chul Park, Sang Hoon Seo, Seong Hyeon Yun, Woo Yong Lee, Hee Cheol Kim, Yong Beom Cho, Yoon Ah Park, Jung Wook Huh, Jung Kyong Shin, Young Suk Park, Jeeyun Lee, Seung Tae Kim, Sung Hee Lim, Ji Eun Shin, Nalee Kim Frontiers in Oncology.2026;[Epub] CrossRef
Analysis of acute genitourinary toxicity in hypofractionated proton beam therapy for localized prostate cancer Wencui Yang, Junetsu Mizoe, Yasuhiro Osaka, Yasuhide Miyabe, Hiroto Seki, Hirotaka Nakamura, Hiromi Sugawara, Naoto Miyajima, Hiromitsu Iwata, Takayuki Hashimoto, Ritsuko Komaki Holistic Integrative Oncology.2026;[Epub] CrossRef
Monte Carlo calculated beam quality correction factors for light ions used in particle therapy Guillaume Houyoux, Hugo Palmans, Nick Reynaert Physics in Medicine & Biology.2026; 71(10): 105025. CrossRef
Advanced radiotherapy and systemic therapy in head and neck adenoid cystic carcinoma: Current progress and future integrated strategies Lihao Liu, Xiaoding Zhou, Lu Li, Jinxin Yang, Mingyu Tan Translational Oncology.2026; 70: 102841. CrossRef
Beyond Photons: Emerging Advances and Clinical Potential of Proton Beam Therapy in Gynecological Malignancies Lifeng Chen, Li Wang, Hamid A. Bakshi Radiation.2026; 6(3): 23. CrossRef
Water calorimetry-based beam quality correction factors for carbon and helium ion beams Lies Verpoest, Séverine Rossomme, Kevin Souris, Thomas Tessonnier, Andrea Mairani, Iván Muñoz, Stephan Brons, Oliver Jäkel, Kilian-Simon Baumann, Hermann Fuchs, Peter Kuess, Alexandros Douralis, Ana Lourenço, Hugo Palmans, John Lee Physics in Medicine & Biology.2026; 71(14): 145006. CrossRef
Tuning the range-energy relationship parameter for Monte Carlo-based proton Bragg curve spreading in muscle, bone, and polymethylmethacrylate Behzad Aminafshar, Hamid Reza Baghani, Ali Asghar Mowlavi Radiological Physics and Technology.2025; 18(1): 300. CrossRef
Evaluation of machine learning models for predicting xerostomia in adults with head and neck cancer during proton and heavy ion radiotherapy Lijuan Zhang, Zhihong Zhang, Yiqiao Wang, Yu Zhu, Ziying Wang, Hongwei Wan Radiotherapy and Oncology.2025; 204: 110712. CrossRef
Physiopathological effects of entrance versus distal spread-out Bragg peak on mouse spinal cord neurons Filippo Torrisi, Francesco Paolo Cammarata, Valentina Bravatà, Marco Calvaruso, Cristiana Alberghina, Anna Maria Pavone, Giada Petringa, Giuseppe Antonio Pablo Cirrone, Simona Denaro, Anna Gervasi, Simona D’Aprile, Nunzio Vicario, Emanuele Scifoni, Pietro Scientific Reports.2025;[Epub] CrossRef
Effect of FLASH proton therapy on primary bronchial epithelial cell organoids Merian E. Kuipers, Floriane van Liefferinge, Ernst van der Wal, Marta Rovituso, Annelies M. Slats, Pieter S. Hiemstra, Krista C.J. Van Doorn-Wink Clinical and Translational Radiation Oncology.2025; 52: 100927. CrossRef
Exploring biochemical considerations for diffusive alpha radiation therapy (DaRT) models Peter Dukakis, Jesús J. Bosque, Alejandro Bertolet Physica Medica.2025; 131: 104947. CrossRef
STAT1 increases the sensitivity of lung adenocarcinoma to carbon ion irradiation via HO-1-mediated ferroptosis Yanliang Chen, Dandan Wang, Hongtao Luo, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Qiuning Zhang, Wenzhen Yuan Molecular and Cellular Biochemistry.2025; 480(7): 4265. CrossRef
Uncertainty evaluation in simulation study on range-shift estimation due to statistical noise in secondary electron bremsstrahlung from a small number of carbon ions Michiko Tsuda, Mitsutaka Yamaguchi, Takuya Yabe, Yuto Nagao, Naoki Kawachi, Makoto Sakai, Tomihiro Kamiya, Wataru Kada, Hiroshi Watabe Japanese Journal of Applied Physics.2025; 64(4): 047001. CrossRef
Monte Carlo simulation of beam quality correction factor kQ
for carbon-ion beams using FLUKA and GATE for selected cylindrical and plane-parallel ionization chambers Jessica Stolzenberg, Pascal Saße, Yuri Simeonov, Björn Poppe, Kilian-Simon Baumann, Hui Khee Looe Physics in Medicine & Biology.2025; 70(8): 085017. CrossRef
Effects of Combined Neutron and Proton Beam Radiation Exposure on the Pool of Breast Cancer Stem Cells In Vitro I. A. Zamulaeva, O. N. Matchuk, K. A. Churyukina, V. O. Saburov, S. N. Koryakin, S. A. Ivanov, A. D. Kaprin, E. A. Krasavin Physics of Particles and Nuclei Letters.2025; 22(1): 77. CrossRef
Eradicating Cancer Stem Cells Using High Linear Energy Transfer Radiation Therapy Part 1: Physics and Radiobiology Daniel M. Koffler, Daniel K. Ebner, Eric J. Lehrer, Fatemeh Fekrmandi, Felix Ehret, Morteza Mahmoudi, Chris Beltran, Daniel M. Trifiletti, Laura Vallow, Michael S. Rutenberg, Jacob Eckstein, Bhargava Chitti, Bryan Johnson, Joseph M. Herman, Walter Tingane Applied Radiation Oncology.2025; 14(2): 1. CrossRef
Carbon-ion radiotherapy induces ferroptosis and M1 macrophage polarization to inhibit the development of gastric cancer by downregulating DHODH Yue Wang, Hongyi Cai Frontiers in Medicine.2025;[Epub] CrossRef
Psychological experience of discharge readiness in head and neck cancer patients undergoing particle radiotherapy: A qualitative study Yiqiao Wang, Yu Zhang, Yu Zhu, Hongwei Wan Supportive Care in Cancer.2025;[Epub] CrossRef
Inflammatory signatures across four photon radiotherapy and proton radiotherapy: mechanisms, mitigation, and quality of life impact Yuting Sheng, Daniel M. Han, Mark R. Wakefield, Yujiang Fang Exploration of Targeted Anti-tumor Therapy.2025;[Epub] CrossRef
Molecular mechanisms of TAM-regulated tumorigenesis and progression in various types of radiotherapy and future prospects of radiation-immunotherapy combinations Luyu Liao, Yuzhao Jin, Wei Mao, Ji Zhu, Qianping Chen Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; 1880(5): 189434. CrossRef
Understanding and Exacerbating the Biological Response of Uveal Melanoma to Proton Beam Therapy Laura Hawkins, Helen Kalirai, Karen Aughton, Rumana N. Hussain, Sarah E. Coupland, Jason L. Parsons Cancers.2025; 17(19): 3104. CrossRef
Experimental study of neutron yield in synchrotron-based carbon ion therapy: implications for neutron capture enhanced particle therapy Yu-Chun Chien, Tung-Sheng Hsieh, Hui-Chia Lin, Chin-Hui Wu, Long-Sheng Lu, Yuan-Hung Wu, Shih-Ming Hsu Physics in Medicine & Biology.2025; 70(24): 245024. CrossRef
Physico-Biochemical Modeling of Radionuclide Behavior in Diffusing Alpha-Emitter Radionuclide Therapy A. A. Ermakova, M. V. Peregudov, A. A. Gorokhova, N. A. Gevorgyan, E. S. Poltorak, M. G. Dzhabrailov, K. G. Karamanyan, K. S. Chizhova, D. V. Kotova, A. S. Khnoeva, A. I. Islamova, N. I. Dzhabilova Meditsinskaya Fizika.2025; (4): 62. CrossRef
Breaking barriers: Stereotactic ablative proton and photon radiation therapy for renal cell carcinoma with extensive metastases: A case report Ming-Wei Ma, Zi-Shen Wang, Hong-Zhen Li, Xian-Shu Gao, Chao Liu, Xue-Ying Ren, Wei-Li Zhang, Kai-Wei Yang Medical Dosimetry.2024; 49(1): 41. CrossRef
Comparing the oncologic outcomes of proton therapy and intensity-modulated radiation therapy for head and neck squamous cell carcinoma Chia-Lun Chang, Kuan-Chou Lin, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu Radiotherapy and Oncology.2024; 190: 109971. CrossRef
The rationale for a carbon ion radiation therapy facility in Australia David I. Thwaites, Dale A. Prokopovich, Richard F. Garrett, Annette Haworth, Anatoly Rosenfeld, Verity Ahern Journal of Medical Radiation Sciences.2024; 71(S2): 59. CrossRef
Review of Recent Improvements in Carbon Ion Radiation Therapy in the Treatment of Glioblastoma Fereshteh Koosha, Mahdieh Ahmadikamalabadi, Mohadesseh Mohammadi Advances in Radiation Oncology.2024; 9(5): 101465. CrossRef
Evaluation of Helium Ion Radiotherapy in Combination with Gemcitabine in Pancreatic Cancer In Vitro Bahar Cepni, Thomas Tessonnier, Ivana Dokic, Stephan Brons, Bouchra Tawk, Andrea Mairani, Amir Abdollahi, Jürgen Debus, Klaus Herfarth, Jakob Liermann Cancers.2024; 16(8): 1497. CrossRef
A review and bibliometric analysis of global research on proton radiotherapy Ge Song, Zhi Zheng, Yingming Zhu, Yaoting Wang, Song Xue Medicine.2024; 103(19): e38089. CrossRef
Assessing the Impact of Charged Particle Radiation Therapy for Head and Neck Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis Mingyu Tan, Yanliang Chen, Tianqi Du, Qian Wang, Xun Wu, Qiuning Zhang, Hongtao Luo, Zhiqiang Liu, Shilong Sun, Kehu Yang, Jinhui Tian, Xiaohu Wang Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Biological Insights and Radiation–Immuno–Oncology Developments in Primary and Secondary Brain Tumors Fabiana Gregucci, Kathryn Beal, Jonathan P. S. Knisely, Paul Pagnini, Alba Fiorentino, Elisabetta Bonzano, Claire I. Vanpouille-Box, Babacar Cisse, Susan C. Pannullo, Philip E. Stieg, Silvia C. Formenti Cancers.2024; 16(11): 2047. CrossRef
Transcriptomic response of prostate cancer cells to carbon ion and photon irradiation with focus on androgen receptor and TP53 signaling Jörg Hänze, Lilly M. Mengen, Marco Mernberger, Dinesh Kumar Tiwari, Thomas Plagge, Andrea Nist, Florentine S. B. Subtil, Ulrike Theiss, Fabian Eberle, Katrin Roth, Matthias Lauth, Rainer Hofmann, Rita Engenhart-Cabillic, Thorsten Stiewe, Axel Hegele Radiation Oncology.2024;[Epub] CrossRef
Dose-averaged linear energy transfer within the gross tumor volume of non-small-cell lung cancer affects the local control in carbon-ion radiotherapy Guangsheng Li, Ningyi Ma, Weiwei Wang, Jian Chen, Jingfang Mao, Guoliang Jiang, Kailiang Wu Radiotherapy and Oncology.2024; 201: 110584. CrossRef
Clinical indications and future directions of carbon-ion
radiotherapy: a narrative review Seo Hee Choi, Woong Sub Koom, Hong In Yoon, Kyung Hwan Kim, Chan Woo Wee, Jaeho Cho, Yong Bae Kim, Ki Chang Keum, Ik Jae Lee The Ewha Medical Journal.2024;[Epub] CrossRef
Circadian rhythms and cancer: implications for timing in therapy Mohamed El-Tanani, Syed Arman Rabbani, Areeg Anwer Ali, Ibrahim Ghaleb Ali Alfaouri, Hamdi Al Nsairat, Israa Hamid Al-Ani, Alaa A. Aljabali, Manfredi Rizzo, Dimitrios Patoulias, Mohammad Ahmed Khan, Suhel Parvez, Yahia El-Tanani Discover Oncology.2024;[Epub] CrossRef
The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center Min Cheol Han, Seo Hee Choi, Chae-Seon Hong, Yong Bae Kim, Woong Sub Koom, Jin Sung Kim, Jaeho Cho, Chan Woo Wee, Changhwan Kim, Jong Won Park, Soorim Han, Heejeong Lee, Hong In Yoon, Ik Jae Lee, Ki Chang Keum Radiation Oncology Journal.2024; 42(4): 295. CrossRef
Molecular genetic signatures of head and neck squamous cell carcinoma and their changes induced by proton irradiation Enar D. Jumaniyazova, Alexandra V. Sentyabreva, Anna M. Kosyreva, Anastasia V. Lokhonina RUDN Journal of Medicine.2024; 28(4): 413. CrossRef
Preservation of Neurocognition after Proton Beam Radiation Therapy for Intracranial Tumors: First Results from REGI-MA-002015 Birgit Flechl, Lisa Konrath, Carola Lütgendorf-Caucig, Milana Achtaewa, Eugen B. Hug, Petra Georg International Journal of Radiation Oncology*Biology*Physics.2023; 115(5): 1102. CrossRef
Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity Farzad Taghizadeh-Hesary, Mohammad Houshyari, Mohammad Farhadi Journal of Cancer Research and Clinical Oncology.2023; 149(9): 6719. CrossRef
Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player Maria Manuela Rosado, Claudio Pioli Cancers.2023; 15(4): 1093. CrossRef
Particle radiotherapy for breast cancer Hanguang Ruan, Masahiko Okamoto, Tatsuya Ohno, Yang Li, Yuan Zhou Frontiers in Oncology.2023;[Epub] CrossRef
Dosimetric comparison of robust angles in carbon-ion radiation therapy for prostate cancer Han-Back Shin, Changhwan Kim, Min Cheol Han, Chae-Seon Hong, Seyjoon Park, Woong Sub Koom, Jin Sung Kim Frontiers in Oncology.2023;[Epub] CrossRef
Particle Reirradiation of Malignant Epithelial and Neuroectodermal Sinonasal Tumors: A Case Series from CNAO Barbara Vischioni, Rossana Ingargiola, Maria Bonora, Sara Ronchi, Anna Maria Camarda, Stefania Russo, Eleonora Rossi, Giuseppe Magro, Alfredo Mirandola, Ester Orlandi Journal of Clinical Medicine.2023; 12(7): 2624. CrossRef
Gold-Nanoparticles-Enhanced Production of Reactive Oxygen Species in Cells at Spread-Out Bragg Peak under Proton Beam Radiation Chang-Yun Lo, Shiao-Wen Tsai, Huan Niu, Fang-Hsin Chen, Hsiao-Chien Hwang, Tsi-Chian Chao, Ing-Tsung Hsiao, Jiunn-Woei Liaw ACS Omega.2023; 8(20): 17922. CrossRef
Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis Yanliang Chen, Hongtao Luo, Ruifeng Liu, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Zhiqiang Liu, Shilong Sun, Qiuning Zhang, Xiaohu Wang Radiation Oncology.2023;[Epub] CrossRef
Particle radiotherapy in the era of radioimmunotherapy Zihan Zhou, Bingjie Guan, Huang Xia, Rong Zheng, Benhua Xu Cancer Letters.2023; 567: 216268. CrossRef
A narrative review of particle therapy in cancer Mayakannan Krishnan, C. P. Ranjith Cancer Research, Statistics, and Treatment.2023; 6(2): 248. CrossRef
Proton Beam Therapy in the Reirradiation Setting of Brain and Base of Skull Tumour Recurrences S. Gaito, N.G. Burnet, M.C. Aznar, G. Marvaso, B.A. Jereczek-Fossa, A. Crellin, D. Indelicato, S. Pan, R. Colaco, R. Rieu, E. Smith, G. Whitfield Clinical Oncology.2023; 35(10): 673. CrossRef
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma Hwa Kyung Byun, Changhwan Kim, Jinsil Seong Clinical and Molecular Hepatology.2023; 29(4): 945. CrossRef
Proton Compared to X-Irradiation Induces Different Protein Profiles in Oral Cancer Cells and Their Derived Extracellular Vesicles Inga Solgård Juvkam, Olga Zlygosteva, Mateusz Sitarz, Bernd Thiede, Brita Singers Sørensen, Eirik Malinen, Nina Jeppesen Edin, Tine Merete Søland, Hilde Kanli Galtung International Journal of Molecular Sciences.2023; 24(23): 16983. CrossRef
DNA Damage Clustering after Ionizing Radiation and Consequences in the Processing of Chromatin Breaks Veronika Mladenova, Emil Mladenov, Martin Stuschke, George Iliakis Molecules.2022; 27(5): 1540. CrossRef
Editorial: Medical Application and Radiobiology Research of Particle Radiation Fei Ye, Chao Sun, Yi Xie, Bing Wang, Lu Cai Frontiers in Public Health.2022;[Epub] CrossRef
The Rise of Particle Beam Therapy: Are We Ready for The Potential Game-Changer? Eui Kyu Chie, Yong Chan Ahn Cancer Research and Treatment.2021; 53(3): 609. CrossRef
Purpose
We investigated the clinical efficacy of immune checkpoint blocker (ICB) therapy for metastatic or advanced melanoma in Korean patients. As well, we assessed whether the effects of ICBs can be enhanced by combination therapy with palliative radiotherapy (RT).
Materials and Methods
We retrospectively reviewed the records of 127 patients with metastatic melanoma who received ICB with or without palliative RT between 2014 and 2018. The melanoma subtypes were classified as follows: chronic sun-damaged (CSD), acral, mucosal, and uveal. The primary endpoint was the objective response rate (ORR).
Results
The overall ORR was 15%, with 11 complete and eight partial responses. ORRs for CSD, acral/mucosal, and uveal melanomas were 50%, 16.5%, and 0%, respectively (p=0.009). In addition to the subtype, stage at treatment, total tumor burden at treatment, and ICB type were significantly associated with ORR (all p < 0.05). Palliative RT was administered in 44% of patients during the treatment, and it did not affect ORR. Clinical responders to ICB therapy exhibited significantly higher 1-year progression-free and overall survival rates than nonresponders.
Conclusion
ORR for ICB monotherapy in Korean patients with melanoma is relatively modest compared with that in Western patients because the non-CSD subtypes are predominant in the Korean population. Our findings regarding combination therapy with ICB provided a rationale for the initiation of our phase II study (NCT04017897).
Citations
Citations to this article as recorded by
Acral lentiginous melanoma. Part II. Staging, surgical management, the role of systemic therapy, shortcomings, and future directions Daniella Jaguan, Sach Thakker, Micah Belzberg, Nina Gulati, Janeth R. Campbell, Brittney K. DeClerck, Vishal A. Patel, Gino K. In Journal of the American Academy of Dermatology.2026; 94(2): 435. CrossRef
Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025 Satoshi Fukushima, Takamichi Ito, Jun Asai, Hiroshi Igaki, Ryota Tanaka, Kenjiro Namikawa, Ayato Hayashi, Akane Minagawa, Takuya Miyagawa, Azusa Miyashita, Dai Ogata, Mao Okumura, Yukiko Kiniwa, Hiroyuki Goto, Takeshi Namiki, Hiroki Hashimoto, Tokimasa Hi The Journal of Dermatology.2025;[Epub] CrossRef
Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook Vahideh Mohammadzadeh, Hoda Atapour-Mashhad, Sedigheh Shahvali, Bahardokht Salehi, Mina Shaban, Maryam Shirzad, Afsaneh Salahvarzi, Marzieh Mohammadi Journal of Nanobiotechnology.2025;[Epub] CrossRef
Confronting Melanoma Radioresistance: Mechanisms and Therapeutic Strategies Ielizaveta Gorodetska, Alexander Schulz, Gerhard Behre, Anna Dubrovska Cancers.2025; 17(16): 2648. CrossRef
Inhibiting Fatty Acid Oxidation Suppresses Acquired Resistance to Standard Chemotherapy in Melanoma Wonyoung Choi, Woojin Ham, Jeong Hwan Park, Sung Hoon Sim, Jung Won Chun, Mingyu Kang, Chaeyoung Kim, Woosol Hong, Eun-Byeol Koh, Joon Hee Kang, Sang Myung Woo, Soo-Youl Kim International Journal of Molecular Sciences.2025; 26(20): 9873. CrossRef
Hydrogels as a Potential Biomaterial for Multimodal Therapeutic Applications Harpreet Kaur, Bishmita Gogoi, Ira Sharma, Deepak Kumar Das, Mohd Ashif Azad, Devlina Das Pramanik, Arindam Pramanik Molecular Pharmaceutics.2024; 21(10): 4827. CrossRef
Injectable hydrogels for personalized cancer immunotherapies Neda Mohaghegh, Amir Ahari, Fatemeh Zehtabi, Claire Buttles, Saya Davani, Hanna Hoang, Kaylee Tseng, Benjamin Zamanian, Safoora Khosravi, Ariella Daniali, Negar Hosseinzadeh Kouchehbaghi, Isabel Thomas, Hamed Serati Nouri, Danial Khorsandi, Reza Abbasghol Acta Biomaterialia.2023; 172: 67. CrossRef
Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis Gaofei Yin, Wei Guo, Zhigang Huang, Xiaohong Chen Melanoma Research.2022; 32(2): 71. CrossRef
The pharmacotherapeutic management of nail unit and acral melanomas Julianne M. Falotico, Shari R. Lipner Expert Opinion on Pharmacotherapy.2022; 23(11): 1273. CrossRef
A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic Disease Jina Kim, Jee Suk Chang, Wonmo Sung, Jin Sung Kim, Tae Hyung Kim, Seo Hee Choi, Kyung Hwan Kim, Heejoo Ko, Hye Sun Lee, Soyoung Jeon, Sang Joon Shin, Mitchell Liu, Robert Olson International Journal of Radiation Oncology*Biology*Physics.2022; 114(5): 883. CrossRef
Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators Hwa Kyung Byun, Jee Suk Chang, Minkyu Jung, Woong Sub Koom, Kee Yang Chung, Byung Ho Oh, Mi Ryung Roh, Kyung Hwan Kim, Choong-Kun Lee, Sang Joon Shin Frontiers in Oncology.2021;[Epub] CrossRef
Effectiveness and safety of immune checkpoint inhibitors in combination with palliative radiotherapy in advanced melanoma: A systematic review Jennifer Ben Shimol, Yuli Guzman-Prado, Maria Karlinskaya, Tima Davidson Critical Reviews in Oncology/Hematology.2021; 167: 103499. CrossRef
Purpose
Although Korea has the highest incidence of gastric cancer worldwide and D2-lymphadenectomies are routinely performed, radiotherapy (RT) practice patterns have not been well studied. Therefore, we examined RT usage trends for neoadjuvant/adjuvant patients and identified factors associated with RT. We also examined survival benefits and net medical cost advantages of adding RT.
Materials and Methods
Patients diagnosed with gastric cancer who underwent gastrectomy from 2002-2013 were identified using National Health Insurance Service-National Sample Cohort.
Results
Annually, 30.9 cases per 100,000 population in crude rate underwent gastrectomy in 230 hospitals and 49.8% received neoadjuvant/adjuvant therapy in 182 hospitals. For neoadjuvant/adjuvant patients, postoperative chemo-RT was administered in 4% of cases in 26 hospitals. No significant trends regarding treatment type were observed over time. Having undergone RT was inversely associated with being ≥ 60 years old and having a low income. Having undergone RT was positively related to having a Charlson comorbidity index ≥ 4, hospital location and hospital volume (≥ 2,000 beds). Significant portions of patients treated with RT in this nation (52%) were concentrated in one large-volume hospital. Use of RT linked to increased cost of primary treatment, yet not to reduced overall medical expense. RT did not influence both on overall and disease-specific survivals after adjusting for potential confounders (p > 0.05).
Conclusion
RT was uncommonly utilized as adjuvant or neoadjuvant treatment by physicians in Korea. Despite intrinsic drawback in this data, we did not find either survival benefit or net medical cost advantage by adding RT in adjuvant treatment.
Citations
Citations to this article as recorded by
Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer Yung-Sung Yeh, Ming-Yii Huang, Cheng-Jen Ma, Ching-Wen Huang, Hsiang-Lin Tsai, Yen-Cheng Chen, Ching-Chun Li, Fang-Jung Yu, Hsiang-Yao Shih, Jaw-Yuan Wang Journal of Oncology.2020; 2020: 1. CrossRef
Opportunities and limitations of CT - assessment of neoadjuvant chemoradiation therapy of gastric cancer T. A. Agababyan, N. K. Silanteva, V. Yu. Skoropad, S. A. Ivanov, A. D. Kaprin, Yu. A. Komin, A. Yu. Usacheva, D. D. Kudryavtsev Research and Practical Medicine Journal.2019; 6(4): 92. CrossRef
Outcomes of radiation therapy for resectable M0 gastric cancer Weipeng Gong, Hongwei Zhao, Shanshan Liu, Jie Guan, Xin Liu, Qingsheng Hou, Zhenyu Zhu, Hongliang Guo Oncotarget.2018; 9(2): 1726. CrossRef
Purpose
The Korean Society of Radiation Oncologists (KOSRO) conducted the Patterns of Care Study (PCS) of radiotherapy (RT) for spine metastases in 2009. The current study was conducted to investigate current practice patterns and compare them with the results of the PCS.
Materials and Methods
The survey questionnaire was composed of 10 questions regarding general information and seven questions for each of two clinical scenarios.
Results
Fifty-four members of the KOSRO answered at least one question on the web-based questionnaire. The yearly number of patients treated who underwent palliative spine RT was greater than 200 in 14 (25.9%), 51 to 100 in 13 (24.1%), and 31 to 50 in 11 respondents (20.4%). Scenario 1 described a patient presenting with cord compressive spine metastasis in multiple bones and liver metastasis from non-small cell lung cancer. Thirty gray (Gy) in 10 fractions was chosen by 35 respondents (64.8%). Scenario 2 described a case of a single spine metastasis without progression after targeted therapy. Thirty Gy in 10 fractions was chosen by 19 respondents (35.2%), and a single fraction or less than four fractions of stereotactic ablative radiotherapy (SABR) were selected by 18 respondents (33.3%). When compared with the 2009 PCS, practice patterns of Korean radiation oncologists had not changed significantly over 5 years, except that SABR emerged as a new treatment modality in the selected population.
Conclusion
The 2014 PCS demonstrated that multiple fraction RT is still preferred in a considerable proportion of Korean radiation oncologists.
Citations
Citations to this article as recorded by
Different decision-making in spine metastasis management among radiation oncologists and orthopedic surgeons: a Korean online survey study Hwa Kyung Byun, Woong Sub Koom, Se-Jun Park, Sang-Il Kim, Jin Ho Kim, Young-Hoon Kim, Bong-Soon Chang, Yong Chan Ahn Frontiers in Neurology.2024;[Epub] CrossRef
The Feasibility of Spinal Stereotactic Radiosurgery for Spinal Metastasis with Epidural Cord Compression Yi-Jun Kim, Jin Ho Kim, Kyubo Kim, Hak Jae Kim, Eui Kyu Chie, Kyung Hwan Shin, Hong-Gyun Wu, Il Han Kim Cancer Research and Treatment.2019; 51(4): 1324. CrossRef
Evaluation of predictive factors of vertebral compression fracture after conventional palliative radiotherapy for spinal metastasis from colorectal cancer Jeongshim Lee, Woo Joong Rhee, Jee Suk Chang, Sei Kyung Chang, Woong Sub Koom Journal of Neurosurgery: Spine.2018; 28(3): 333. CrossRef
Spine Metastasis Practice Patterns among Korean, Chinese, and Japanese Radiation Oncologists: A Multinational Online Survey Study Jeong Il Yu, Hee Chul Park, Yong Chan Ahn, Xian-Shu Gao, Jun-Jie Wang, Zhao-Chong Zeng, Yoshinori Ito, Tatsuya Ohno, Yasumasa Nishimura Journal of Radiation Research.2017; 58(1): 155. CrossRef
Nephrologists' likelihood of referring patients for kidney transplant based on hypothetical patient scenarios Ankita Tandon, Ming Wang, Kevin C. Roe, Surju Patel, Nasrollah Ghahramani Clinical Kidney Journal.2016; 9(4): 611. CrossRef
The Effect of Perioperative Radiation Therapy on Spinal Bone Fusion Following Spine Tumor Surgery Tae-Kyum Kim, Wonik Cho, Sang Min Youn, Ung-Kyu Chang Journal of Korean Neurosurgical Society.2016; 59(6): 597. CrossRef
Purpose The aim of this study was to examine the clinical implications of a pathologically complete response after neoadjuvant chemoradiotherapy (CRT) followed by local excision for patients with cT2 rectal cancer who refused radical surgery. Materials and Methods Seventeen patients with cT2 primary rectal cancer within 6 cm from the anal verge who received neoadjuvant CRT and local excision because of patient refusal of radical surgery or poor performance status were included. Two patients had clinical involvement of a regional lymph node. Preoperative radiotherapy was delivered to the whole pelvis at a dose of 44 to 50.4 Gy in 22 to 28 fractions. All patients underwent transanal excision and eight patients (47%) received postoperative chemotherapy. Results Ten patients (59%) achieved ypT0. At a median follow-up period of 75 months (range, 22 to 126 months), four (24%) patients developed recurrence (two locoregional and two distant). The 5-year disease-free survival of all patients was 82%, and was higher in patients with ypT0 (90%) than in patients with ypT1-2 (69%, p=0.1643). Decreased disease-free survival was also observed in patients receiving capecitabine compared with 5-fluorouracil (54% vs. 100%, p=0.0298). Conclusion Local excision could be a feasible alternative to radical surgery in patients with ypT0 after neoadjuvant CRT for cT2 distal rectal cancer without further radical surgery.
Citations
Citations to this article as recorded by
Towards personalized treatment of T2N0 rectal cancer: A systematic review of long‐term oncological outcomes of neoadjuvant therapy followed by local excision Roberto Peltrini, Nicola Imperatore, Maria Michela Di Nuzzo, Gianluca Pellino Journal of Gastroenterology and Hepatology.2022; 37(8): 1426. CrossRef
Preoperative concurrent chemoradiotherapy MRI characteristics favouring pathologic complete response in patients with rectal cancer: Usefulness of MR T2‐stage as an ancillary finding for predicting pathologic complete response Hyeon Jin Lee, Woo‐Suk Chung, Ji hae An, Jung Hoon Kim Journal of Medical Imaging and Radiation Oncology.2021; 65(2): 166. CrossRef
MR prediction of pathologic complete response and early-stage rectal cancer after neoadjuvant chemoradiation in patients with clinical T1/T2 rectal cancer for organ saving strategy Heejin Bae, Nieun Seo, Kyunghwa Han, Woong Sub Koom, Myeong-Jin Kim, Nam Kyu Kim, Joon Seok Lim Medicine.2020; 99(42): e22746. CrossRef
Does total regression of primary rectal cancer after preoperative chemoradiotherapy represent “no tumor” status? Seong-A Jeong, In Ja Park, Seung Mo Hong, Jun Woo Bong, Hye Yoon Choi, Ji Hyun Seo, Hyong Eun Kim, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim Annals of Surgical Treatment and Research.2019; 96(2): 78. CrossRef
Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection Oliver K. Jawitz, Mohamed A. Adam, Megan C. Turner, Brian F. Gilmore, John Migaly Surgery.2019; 165(6): 1193. CrossRef
Status for clinically complete remission rectal cancer after concomitant chemo-radiotherapy in Taiwan Geng-Ping Lin, Kuan-Der Lee, Jeng-Yi Wang, Jinn-Shiun Chen, Chun-Ju Chiang, Chien-Yuh Yeh Asian Journal of Surgery.2018; 41(3): 203. CrossRef
Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer Laurence Bernier, Svetlana Balyasnikova, Diana Tait, Gina Brown Current Colorectal Cancer Reports.2018; 14(2): 37. CrossRef
Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score–Matched Analysis Young Seob Shin, Jin-hong Park, Sang Min Yoon, Jin Cheon Kim, Chang Sik Yu, Seok-Byung Lim, In Ja Park, Tae Won Kim, Yong Sang Hong, Kyu-pyo Kim, Eun Kyung Choi, Seung Do Ahn, Sang-Wook Lee, Jong Hoon Kim International Journal of Radiation Oncology*Biology*Physics.2018; 101(3): 630. CrossRef
Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy? Bo Young Oh, Jung Wook Huh, Woo Yong Lee, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun Cancer Research and Treatment.2018; 50(3): 634. CrossRef
Local Excision Techniques for Rectal Cancer After Neoadjuvant Chemoradiotherapy: What Are We Doing? Fraser McLean Smith, Abdul Ahad, Rodrigo Oliva Perez, John Marks, Krzysztof Bujko, Richard J. Heald Diseases of the Colon & Rectum.2017; 60(2): 228. CrossRef
Transanal Minimally Invasive Surgery: Review of Indications and Outcomes from 75 Consecutive Patients Deborah S. Keller, Reena N. Tahilramani, Juan R. Flores-Gonzalez, Ali Mahmood, Eric M. Haas Journal of the American College of Surgeons.2016; 222(5): 814. CrossRef
Lymphknotenmetastasen beim ypT1/2-Rektumkarzinom nach neoadjuvanter Radiochemotherapie T. Sprenger, H. Rothe, T. Beissbarth, L.-C. Conradi, A. Kauffels, K. Homayounfar, C. L. Behnes, C. Rödel, T. Liersch, M. Ghadimi Der Chirurg.2016; 87(7): 593. CrossRef
Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer Sung Min Jung, Chang Sik Yu, In Ja Park, Tae Won Kim, Jong Hoon Kim, Yong Sik Yoon, Seok-Byung Lim, Jin Cheon Kim Medicine.2016; 95(20): e3718. CrossRef
A Systematic Review of Local Excision After Neoadjuvant Therapy for Rectal Cancer: Are ypT0 Tumors the Limit? Sally Hallam, David E. Messenger, Michael G. Thomas Diseases of the Colon & Rectum.2016; 59(10): 984. CrossRef
Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer Young Seob Shin, Yong sik Yoon, Seok-Byung Lim, Chang Sik Yu, Tae Won Kim, Heung Moon Chang, Jin-hong Park, Seung Do Ahn, Sang-Wook Lee, Eun Kyung Choi, Jin Cheon Kim, Jong Hoon Kim Radiation Oncology Journal.2016; 34(3): 177. CrossRef
Why the Conventional Parks Transanal Excision for Early Stage Rectal Cancer Should Be Abandoned Sam Atallah, Deborah Keller Diseases of the Colon & Rectum.2015; 58(12): 1211. CrossRef
Influence of Preoperative Chemoradiotherapy on the Surgical Strategy According to the Clinical T Stage of Patients With Rectal Cancer In Ja Park, Jong Lyul Lee, Yong Sik Yoon, Chan Wook Kim, Seok-Byung Lim, Jong Seok Lee, Seong Ho Park, Jin Hong Park, Jong Hoon Kim, Chang Sik Yu, Jin Cheon Kim Medicine.2015; 94(52): e2377. CrossRef
Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation Juefeng Wan, Kaitai Liu, Ji Zhu, Guichao Li, Zhen Zhang Oncotarget.2015; 6(13): 11714. CrossRef
Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: Pooled analysis of KROG 10-01 and 11-02 Jong Hoon Lee, Hong Seok Jang, Jun-Gi Kim, Myung Ah Lee, Dae Yong Kim, Tae Hyun Kim, Jae Hwan Oh, Sung Chan Park, Sun Young Kim, Ji Yeon Baek, Hee Chul Park, Hee Cheol Kim, Taek-Keun Nam, Eui Kyu Chie, Ji-Han Jung, Seong Taek Oh Radiotherapy and Oncology.2014; 113(1): 18. CrossRef